GlassScriptPrepare for your visit
Richard M Arnold
Endocrinology, Diabetes & Metabolism · New York, NY · NPI 1750300380
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$8,384.74
in general payments reported to CMS, 2019-2025 · $304 in 2025
The $304 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Who reported paying
General payments only, top 6 by amount.
- Lilly USA, LLC $1,579.94
- Horizon Therapeutics Plc $961.05
- Novo Nordisk INC $870.15
- Intra-Sana Laboratories $760.88
- Astrazeneca Pharmaceuticals LP $677.03
- Amgen INC. $647.11
Drugs and devices associated with these payments
Ilet Bionic Pancreas Reltone 400 Mg Reltone 200 Mg Glycate Tepezza Mounjaro Quviviq Evenity Ilet Insulin Infusion Kit Inset Ilet Insulin Infusion Kit Contact Detach Recorlev Kerendia
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Richard Arnold listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/170730/richard-m-arnold